Apellis Pharmaceuticals, Inc. (APLS) Insider Ownership

Historic Insider Ownership Trends

Through the 90-day period concluding February 10, 2026, Apellis Pharmaceuticals's top three insider stakeholders include TenPercentOwner Venture Investments Ltd Morningside (12.81Mn shares), Chief Scientific Officer Pascal Deschatelets (1.18Mn shares), Chief Executive Officer Cedric Francois (798.78K shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares Report Date
Venture Investments Ltd Morningside 12,806,342 18 Nov, 2021
Pascal Deschatelets Chief Scientific Officer 1,177,222 30 Jan, 2026
Cedric Francois Chief Executive Officer 798,783 05 Feb, 2026
Alec Machiels 396,939 05 Jan, 2026
Timothy Eugene Sullivan Chief Financial Officer 212,437 30 Jan, 2026
David O. Watson General Counsel 194,653 30 Jan, 2026
A. Sinclair Dunlop 191,709 05 Jan, 2026
Kelley Boucher Chief People Officer 127,804 30 Jan, 2026
Nur Nicholson Chief Technical Officer 116,338 30 Jan, 2026
Mark Jeffrey Delong Chief Business & Strat Officer 114,959 30 Jan, 2026
Leslie Meltzer Chief Research And Development 107,024 30 Jan, 2026
Federico Grossi Chief Medical Officer 94,884 09 Jan, 2023
Caroline Baumal Chief Medical Officer 86,527 23 Jan, 2026
Adam J. Townsend Chief Commercial Officer 84,050 30 Jan, 2025
Karen Lewis Chief People Officer 70,251 30 Jan, 2025
Lukas Scheibler Chief Research Officer 68,299 05 Dec, 2023
James George Chopas Vp/Chief Accounting Officer 65,955 30 Jan, 2026
Jeffrey Eisele Chief Development Officer 55,312 30 Jan, 2025
Paul R. Fonteyne 30,666 05 Jan, 2026
Stephanie Monaghan O'Brien 25,666 05 Jan, 2026
Gerald Chan 25,666 05 Jan, 2026
Craig A Wheeler 24,444 05 Jan, 2026
Victoria L. Brown Program Team Lead 23,556 24 Jan, 2023
Keli Walbert 17,051 05 Jan, 2026
Nicole D Perry Vice President Accounting 4,847 03 Aug, 2021

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
03 Feb, 2026 Cedric Francois Common Stock A 8,840 $3.76 490,837 D M
28 Jan, 2026 David O. Watson Common Stock A 55,986 $0.00 144,517 D A
28 Jan, 2026 Pascal Deschatelets Common Stock A 25,840 $0.00 1,177,222 D A
28 Jan, 2026 Cedric Francois Common Stock A 195,952 $0.00 481,997 D A
28 Jan, 2026 Timothy Eugene Sullivan Common Stock A 58,140 $0.00 152,041 D A
28 Jan, 2026 Nur Nicholson Common Stock A 45,220 $0.00 116,338 D A
28 Jan, 2026 James George Chopas Common Stock A 16,150 $0.00 65,955 D A
28 Jan, 2026 Mark Jeffrey Delong Common Stock A 36,606 $0.00 114,959 D A
28 Jan, 2026 Kelley Boucher Common Stock A 30,146 $0.00 127,804 D A
28 Jan, 2026 Leslie Meltzer Common Stock A 45,220 $0.00 107,024 D A
22 Jan, 2026 David O. Watson Common Stock D 7,832 $21.77 88,531 D S
22 Jan, 2026 Pascal Deschatelets Common Stock D 5,928 $21.77 1,151,382 D S
22 Jan, 2026 Cedric Francois Common Stock D 27,192 $21.77 286,045 D S
22 Jan, 2026 Timothy Eugene Sullivan Common Stock D 10,287 $21.77 93,901 D S
22 Jan, 2026 Nur Nicholson Common Stock D 7,725 $21.77 71,118 D S
22 Jan, 2026 James George Chopas Common Stock D 2,064 $21.77 49,805 D S
22 Jan, 2026 Mark Jeffrey Delong Common Stock D 3,371 $21.77 78,353 D S
22 Jan, 2026 Caroline Baumal Common Stock D 2,797 $21.77 86,527 D S
20 Jan, 2026 David O. Watson Common Stock D 2,475 $19.79 96,363 D S
20 Jan, 2026 Pascal Deschatelets Common Stock D 909 $19.79 1,157,310 D S